News UK blood cancer patients get early access to BMS drug Nivolumab made available ahead of EU approval in relapsed cHL.
News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
